雌激素与非小细胞肺癌关系的研究进展  

Advances in Association of Estrogen and Human Non-small Cell Lung Cancer

作　　者：何涓[1] 宋鑫[1] 

机构地区：[1]昆明医科大学第三附属医院肿瘤生物治疗中心,昆明650118

出　　处：《中国肺癌杂志》2015年第5期315-320,共6页Chinese Journal of Lung Cancer

基　　金：国家高科技研究发展计划(863)(No.2012AA02A201);国家自然科学基金资助项目(No.81260307;No.81360322;No.81470005)资助~~

摘　　要：肺癌死亡率位居全球癌症之首,其中约85%为非小细胞肺癌(non-small cell lung cancer,NSCLC)。虽然其治疗手段有所提高,但死亡率仍然居高不下。越来越多的证据表明,雌激素及雌激素受体参与了NSCLC的发生和发展。雌激素受体调节剂及芳香化酶抑制剂能够逆转NSCLC患者对铂类化疗药物的耐药性,并能增强表皮生长因子受体的酪氨酸酶抑制剂的疗效。本文就雌激素系统及抗雌激素治疗在NSCLC中的作用作一综述。Lung cancer, of which approximately- 85% are non-small cell lung cancer （NSCLC）, is the most leading cause of cancer mortality throughout the world. Despite recent improvements in its treatment, it still remains a highly lethal disease. It is becoming increasingly clear that estrogen and estrogen receptors are involve in the pathogenesis and development of lung cancer. Estrogen receptor modulators and aromatase inhibitor may reverse the drug-resistance of platinum based che- motherapy in NSCLC patients and can enhance curative effect of epidermal growth factor receptor tyrosine kinase inhibitor. In this article the progress in the function of estrogen in NSCLC and the treatment based on the ER signaling pathways for NSCLC is reviewed.

关 键 词：肺肿瘤 雌激素 雌激素受体 抗雌激素治疗 

分 类 号：R734.2[医药卫生—肿瘤]